PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30580239-3	2019	In this study, a class of 2-benzyloxybenzamides were discovered as novel SMS2 inhibitors through scaffold hopping and structural optimization.	2-benzyloxybenzamides	26-47	sphingomyelin synthase 2	Mus musculus	73-77	
30580239-4	2019	Among them, Ly93 as one of the most potent inhibitors exhibited IC50 values of 91 nM and 133.9 muM against purified SMS2 and SMS1 respectively.	Ly93	12-16	sphingomyelin synthase 2	Mus musculus	116-120	
30580239-4	2019	Among them, Ly93 as one of the most potent inhibitors exhibited IC50 values of 91 nM and 133.9 muM against purified SMS2 and SMS1 respectively.	Ly93	12-16	sphingomyelin synthase 1	Mus musculus	125-129	
30580239-5	2019	The selectivity ratio of Ly93 was more than 1400-fold for purified SMS2 over SMS1.	Ly93	25-29	sphingomyelin synthase 2	Mus musculus	67-71	
30580239-5	2019	The selectivity ratio of Ly93 was more than 1400-fold for purified SMS2 over SMS1.	Ly93	25-29	sphingomyelin synthase 1	Mus musculus	77-81	
30580239-6	2019	The in vitro studies indicated that Ly93 not only dose-dependently diminished apoB secretion from Huh7 cells, but also significantly reduced the SMS activity and increased cholesterol efflux from macrophages.	Ly93	36-40	apolipoprotein B	Homo sapiens	78-82	
30580239-9	2019	As a potent selective SMS2 inhibitor, Ly93 significantly decreased the plasma SM levels of C57BL/6J mice.	Ly93	38-42	sphingomyelin synthase 2	Mus musculus	22-26	
30580239-10	2019	Furthermore, Ly93 was capable of dose-dependently attenuating the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice treated with Ly93.	Ly93	13-17	apolipoprotein E	Mus musculus	168-184	
30580239-11	2019	In conclusion, we discovered a novel selective SMS2 inhibitor Ly93 and demonstrated its anti-atherosclerotic activities in vivo.	Ly93	62-66	sphingomyelin synthase 2	Mus musculus	47-51